dsRNA PCSK9 Gene Silencing via RNA Interference

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for agents that can inhibit PCSK9 gene expression to treat diseases such as hyperlipidemia, which are associated with the aberrant regulation of the PCSK9 gene.

Innovation Solution

The use of double-stranded ribonucleic acid (dsRNA) to silence PCSK9 expression by targeting specific sequences of the PCSK9 mRNA, thereby inhibiting its expression in cells and treating associated pathological conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If double-stranded RNA is used to inhibit PCSK9 gene expression, then PCSK9 expression is suppressed by at least 40%, but the complexity of the therapeutic approach increases

Engineering Contradiction:

ImprovePCSK9 expression inhibition efficacyVSAvoidtherapeutic approach complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses double-stranded RNA as an intermediary molecule to mediate the inhibition of PCSK9 gene expression. The dsRNA acts as a mediator between the therapeutic goal (lowering PCSK9) and the biological mechanism (RNA interference pathway), triggering cellular processes that lead to gene silencing without requiring direct manipulation of the gene itself.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces traditional mechanical or chemical inhibition approaches with a biological mechanism (RNA interference). Instead of using small molecules or proteins to inhibit PCSK9, the invention utilizes the cell's own RNAi machinery to achieve gene silencing, substituting a biochemical system for more conventional therapeutic mechanisms.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If dsRNA targets specific PCSK9 mRNA sequences, then gene expression is silenced effectively, but the precision of target sequencing requirements increases

Engineering Contradiction:

Improvegene silencing efficacyVSAvoidtarget sequence complementarity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies local quality by designing dsRNA molecules with specific regions of complementarity (19-30 nucleotides) that are precisely matched to target PCSK9 mRNA sequences. Not all regions of the dsRNA need perfect complementarity - only the critical seed region and adjacent nucleotides require high precision, while other regions can tolerate more variation, allowing for optimized design that balances efficacy with manufacturing feasibility.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dsRNA effectively inhibits PCSK9 gene expression by at least 40%, leading to significant reduction in LDL cholesterol levels and providing a therapeutic approach for hyperlipidemia and other related diseases.

Implementation Method 1

double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference to inhibit the expression of the PCSK9 gene

Methodology Applied

Scientific EffectRNA interference:

Data Source

PatentUS20250171785A1Compositions and methods for inhibiting expression of the PCSK9 gene

Publication Date: 2025.05.29 ALNYLAM PHARMACEUTICALS INC

AI summary

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.